Citations
Google Scholar:
Lookup
Altmetric:
Date
2026-09-01
Abstract
Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality worldwide, creating an urgent need for novel therapeutic strategies and advanced manufacturing processes that are scalable and cost effective. Peptide-based drugs offer high specificity, potency, and favorable safety, yet their translation is limited by poor stability, enzymatic degradation, and low bioavailability. Supercritical carbon dioxide (scCO₂) has emerged as a promising technology to address these challenges through versatile formulation options, including polymeric and lipid nanoparticles and liposomes. This review discusses promising cardiovascular peptide therapeutics, summarizes key formulation strategies, the limitations of current manufacturing techniques and the main characteristics of various scCO₂-based processes for peptide formulation development. The advantages of scCO₂ over conventional methods, including enhanced product quality, the ability to process thermosensitive compounds at low temperatures, and minimal/no use of organic solvents, are discussed alongside current challenges, scale-up considerations, and knowledge gaps. Finally, future directions and translational opportunities are considered, emphasizing the potential of scCO₂ as an enabling platform for next-generation peptide therapeutics in cardiovascular health.
Supervisor
Description
Publisher
Elsevier
Citation
European Journal of Pharmaceutical Sciences 224, 107598
Collections
Chemical Sciences
Show all metadata
Files
Thumbnail Image
Costa_2026_Innovative.pdf
Adobe PDF, 6.09 MB
Keywords
cardiovascular diseases, angiotensin, nano-encapsulation, supercritical CO2, liposomes
ULRR Identifiers
https://hdl.handle.net/10344/32018
 https://doi.org/10.34961/19621
Funding code
Funding Information
Sustainable Development Goals
(3) Good Health and Well-Being
External Link
License
Attribution-NonCommercial-ShareAlike 4.0 International
cbn
Embedded videos